RxDoctor Payments DataLook up a doctor →

Lonny Yarmus, DO

Pulmonary Disease · Baltimore, MDNPI 1548367790

Payments from drug & device makers

$1,188,157in general payments, 2019–2025

Across 566 payments — averaging $2099.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Veran Medical Technologies, Inc.$437K
  • AstraZeneca$296K
  • Erbe Elektromedizin GmbH$162K
  • Fujifilm Healthcare Americas Corporation$42K
  • Olympus Corporation Of The Americas$39K
  • Intuitive Surgical$29K
  • plus $183K from 24 others
$17,110in research payments, 2019–2025

Across 1 payment — averaging $17,110 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • United Therapeutics Corporation$17K

What the payments were for

  • Consulting fees$309,67153%
  • Speaking & faculty fees$141,63924%
  • Travel & lodging$85,40215%
  • Food & beverage$20,0093%
  • Education$25,0804%
  • Gifts$930%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,188,157 in reported general payments places this provider in the 95th percentile of 297 pulmonary disease providers in Maryland.

See all pulmonary disease providers in Maryland

Medicare billing

Part B allowed, 2024
$33,233
Medicare patients
133
Services billed
295

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pulmonary disease in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →